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Abstract Originally identified as multicopy suppressor of a le- 
thal growth arrest caused by expression of a tumour mutant 
cDNA of p53 in fission yeast the tmsl gene product was found 
to form stable complexes with p53 in yeast. By using purified 
recombinant proteins multimeric complexes of tmsl and p53 
could be demonstrated and recently the p53 binding site on the 
tmsl protein was established to the sequence YYITTEDFCT (aa 
116-125) in the vicinity of a well conserved cell division motif. 
Here we report the precise mapping of the tmsl binding site on 
the p53 protein to the sequence LQIRGRERFE (aa 330-339) 
which defines a new functional domain on the p53 protein. 
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1. Introduction 
The growth suppressor p53 apppears to play a key role in the 
cetlular growth control [1]. Loss of p53 activity by mutation, 
re trrangement or loss of both alleles results in selective growth 
ativantage and favours cell transformation which is mirrored 
bx a broad spectrum of p53 mutations in various human tu- 
m)urs [2-4]. Irradiation or DNA damaging agents lead to an 
increase of p53 expression resulting in G1 growth arrest [5-7] 
o~ apoptosis [8,9]. Wild type p53 binds double stranded DNA 
specifically [10-12] and was found to transactivate he expres- 
si, )n of various genes omehow involved in cell growth [13-17]. 
There are three different functional domains of the p53 protein: 
a~ N-terminal domain which is responsable for the transactiva- 
ti(,n properties of p53 [13], a central core domain which specif- 
ically binds DNA [18] and the C-terminal domain which con- 
tams nuclear localization sequences and is required for the 
oh gomerisation ofp53 proteins [19,20]. The C-terminal domain 
se,~ms to be also important for the regulation of the DNA 
bi ading ability of p53. Phosphorylation byprotein kinase CK2, 
deletion of the last 30 amino acids or binding of the monoclonal 
al~tibody PAb421 stimulates the DNA binding of p53 [12]. The 
la ter findings led to the proposal that some yet unknown cellu- 
la  proteins might be responsible for modulating the DNA 
biading properties of p53 by binding to C-terminal sequences 
a id  convert p53 assembled into oligomers between latent and 
at tivated forms by allosteric transitions [21]. Since the number 
oI p53 binding proteins which are thought to modulate p53 
function is still increasing [22] it is of central importance to 
elucidate their functions and study complex formation in more 
detail. Among the candidates i  the fl-subunit of protein kinase 
CK2 [23] because it was recently demonstrated that p53 is not 
or, ly phosphorylated at a C-terminal amino acid residue by 
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protein kinase CK2, but also binds to the fl-subunit of protein 
kinase CK2 via C-terminal sequences [24,25]. Another good 
candidate might be the tmsl protein. Originally identified as 
multicopy suppressor of a p53 induced growth arrest in fission 
yeast [26] the tmsl protein was found to form stable complexes 
with p53 in yeast [27]. By using purified recombinant proteins 
multimeric omplexes of tmsl and p53 could be demonstrated 
and the binding site was localized to the C-terminal part of p53 
[27]. There is evidence that the tms 1 protein might be conserved 
during evolution. As previously reported a polyclonal antibody 
raised against recombinant tmsl protein was used to analyze 
mammalian cells for the expression of a tmsl-related protein. 
We could identify a 42 kDa protein which forms complexes 
with p53 in vivo. In addition this tmsl-related 42 kDa protein 
was localized to the nucleus of various mammalian cell lines 
[28]. More recently we were able to establish the p53 binding 
site on the tmsl protein to the sequence YITTEDFCT (aa 
1 lf~125) in the vicinity of a well conserved cell division motif 
[29]. Since this approach ad proven sucessful we now mapped 
the tmsl binding site within the C-terminal part of p53 to the 
sequence LQIRGRERFE (aa 330-339) which defines a new 
functional domain on the p53 protein. 
2. Experimental 
2.1. Expression and purification of recombinant proteins 
The p53 cDNA was modified by PCR to introduce appropiate 
BamHI and HindlII restriction sites respectively. 5'primers contained 
in addition a cAMP-dependent protein kinase site [30]. The amplified 
fragments were cloned into the pQE30 vector (DIAGEN) to produce 
plasmids pQE30-CT 264-393 (amino acids 264-393 of p53), pQE30-CT 
287-393 (amino acids 287-393 of p53) and pQE30-CT 34(~393 (amino 
acids 340-393 of p53). The plasmid for the tmsl fragment was as 
described [25]. Transformed E. coli (HB101) were grown to early log 
phase and induced for 3 hours with lmM IPTG. Cells from 11 bacterial 
cultures were pelleted, washed with 50 mM Tris-HCl, pH 8.0, 0.1 M 
NaCI and resuspended in 6 M guanidine hydrochloride, 0.1 M sodium 
phosphate, pH 8.0, and lysed overnight at 4°C. After precipitating 
cellular debris the clearified supernatants were applied onto Ni2+-NTA 
agarose (DIAGEN) [31]. The chelate resins were washed with 10 vol- 
umes each of lysing buffer. Bound proteins were eluted with lysing 
buffer, pH 4.0, and dialyzed against 20 mM Tris-HC1, pH 8.0, 300 mM 
KCI, 0.1% Tween 20 to allow refolding and proteins were analyzed by 
SDS-PAGE and checked by immuno blot analysis as described previ- 
ously [32]. 
2.2. Labelling of recombinant proteins 
According to the manufacturer's recommendations about 30/.tg each 
of recombinant purified proteins were labelled for 30 minutes at 37°C 
with heart muscle cAMP dependent protein kinase (Sigma). 
2.3. West- Western blot analysis 
Total lysates of C-terminal p53 peptides expressing E. coli cells were 
subjected to SDS-PAGE without boiling prior to loading the gel. After 
renaturation in 200 ml 10 × PBS at 4°C for 1 hour proteins were trans- 
ferred onto nitrocellulose filters. Filters were blocked for 1 hour at 4°C 
with dialysis buffer and probed with 20 ~tg of labelled purified tmsl 
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fragments for 1 hour at 4°C under gentle agitation. After washing two 
times with dialysis buffer filters were subjected to autoradiography. 
2.4. Peptide synthesis 
A set of 11 peptides of 10 amino acid long sections of amino acid 285 
to 344 of the C-terminus of p53 that consecutively overlapped by five 
amino acids were synthesized by means of the SPOTs method (CRB, 
England) according to the manufacturer's recommendations. 
3. Results and discussion 
There is an increasing body of evidence that the carboxy- 
terminal domain of p53 is subject for the negative modulation 
of its ability to act as growth suppressor. Apart from phospho- 
rylation of the C-terminus of p53 by cyclin-dependent kinases 
[33-35] and protein kinase CK2 [25,36] the complex formation 
with cellular proteins appears to play an important role for the 
conversion between latent and activated forms of p53 by allo- 
steric transitions [21]. Recently we showed that an overexpres- 
sion of the fission yeast ms 1 protein is capable to abrogate the 
growth suppressor activity of human p53 when expressed in 
yeast [26]. Coexpression of tmsl and human p53 lead to stable 
multimeric omplexes of tmsl and p53 in yeast. In vitro the 
interaction was mapped to the carboxy-terminal part of p53 by 
west-Western blot analysis using purified recombinant proteins 
[27]. In order to narrow down the tmsl binding region on the 
C-terminus of p53 we constructed expression plasmids pQE30- 
CT264-393, pQE30-CT28v 393 and pQE30-CT340_393 of human p53 
respectively. The fragment of amino acids 287-393 of p53 was 
chosen because the fragment lacks the highly conserved box V 
whereas the fragment of amino acids 340-393 is known to 
contain the tetramerization domain of p53. Fig. 1A shows ly- 
sates of E. coli cells expressing the various C-terminal frag- 
ments analysed on a 15% SDS polyacrylamide g l and subse- 
quently stained by Coomassie blue to demonstrate he expres- 
sion of p53 fragments of the appropiate size. No comparable 
protein could be seen in non-transformed bacteria s it is shown 
in Fig. 1A, lane C. By probing a Western blot of the lysates with 
a p53 specific monoclonal antibody PAb 421 which recognizes 
30--  ~. .  
16-- . ~b'l~r. 
A 
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Fig. 1. Expression, immunoblot analysis and west-Western blot of 
C-terminal p53 fragments. E coli strain HB101 was transformed with 
plasmids pQE30-CT26~393, pQE30-CT287 393 and pQE30-CT340_393, re- 
spectively. Protein expression was induced by addition of IPTG. Ali- 
quots of total bacterial lysates (as a control a bacterial lysates of non- 
transformed E. coli cells was added; C lanes) were analysed on 15% 
SDS-polyacrylamide g ls and either stained with Coomassie blue (A) 
or proteins were transferred onto a nitrocellulose filter which was 
analysed by Western blot using the p53 specific monoclonal antibody 
PAb421 followed by ECL development (B) or proteins were renatured 
in the gel before transfer on nitrocellulose and subsequently incubated 
with purified and 32P-labelled tmsl protein. 
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Fig. 2. Overview of C-terminal fragments. Numbers indicate amino 
acids on the polypeptide chain of p53. 
tins1 binding site 
Gl l  aa 344 
8 GEYFTLQIRG 
7 KKPLDGEYFT 
6 SPQPKKKPLD 
5 NNTSSSPQPK 
4 KRALPNNTSS 
3 PPGSTKRALP 
2 PHHELPPGST 
1 RKKGEPHHEL 
EEENLRKKGE 
aa285 
Fig. 3. Sequences ofthe synthetic p53-derived peptides immobilised on 
a membrane. Numbers indicate individual peptides ranging from amino 
acids 285 to 344 (aa285 to aa 344). 
a C-terminal epitope on p53 spanning amino acids 370-378 [37] 
we verified the identity of the expressed fragments (Fig. 1B). 
For the expression of tmsl protein in E. coli we used a pQE30- 
tms 1 plasmid introducing six histidine residues and a phospho- 
rylation site for cAMP-dependent protein kinase to the N- 
terminus of the tmsl protein. This allows a rapid single step 
purification of recombinant tmsl protein on a Ni2+-NTA aga- 
rose column and radiactive labelling of purified protein with 
commercially available heart muscle cAMP-dependent protein 
kinase (Sigma) as described previously [27]. The purified 32p_ 
labelled tmsl protein was used as probe in the west-Western 
blot analysis on nitrocellulose filters from total E. coli lysates 
containing the various C-terminal fragments of p53. As shown 
in Fig. I C all fragments except for the C-terminal deletion 
fragment spanning amino acids 340-393 were capable of bind- 
ing the tmsl protein indicating that the binding site lies within 
the region of amino acid 287 to 340 as indicated in Fig. 2. This 
region spanning amino acid 287 to 340 of p53 had previously 
been shown to be critical for the interaction of p53 with the 
fl-subunit of protein kinase CK2 and is seemingly representing 
a new functional domain for modulating p53 function [25,36]. 
Since the systematic screening of series of short peptide se- 
quences has become a powerful approach for characterising 
protein-protein teractions we used a synthetic approach to 
narrow down the tmsl binding domain on the C-terminus of 
p53 by means of the SPOTs method. The SPOTs method allows 
the rapid solid phase synthesis of peptides immobilised on a 
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cellulose membrane ina format suitable for systematic analysis 
of protein-protein i teractions or antibody epitope mapping. 
This method had already proven sucessful for the mapping of 
the p53 binding site on the tmsl protein [29] and the precise 
delinition of the epitopes of three different monoclonal anti- 
bodies raised against recombinant tmsl protein [38,39]. First 
we synthesized a set of 11 overlapping peptides of 10 amino acid 
lolg sections of the p53 primary amino acid sequence spanning 
tht tmsl binding region from amino acid 285 to 344 as indicated 
in Fig. 3. After blocking the filter was probed with labelled 
pu "ified tmsl protein, washed and subjected to autoradiogra- 
ph 1. As shown in Fig. 4 this resulted in binding oftmsl protein 
to peptides No. 9, 10 and 11 with a remarkable specificity 
incicating a strong interaction between the tmsl protein and 
tht p53-derived peptides. Since these identified peptides over- 
lal ped by the sequence LQIRGRERFE (aa 330 339) we con- 
chded that the tmsl binding domain appears to be a single site 
ret resenting a new functional domain on the p53 protein. 
~,ecently it has been established that amino acids 319-360 
co ~stitute the minimal tetramerization u it of p53 and the three 
di] aensional structure of the tetramerization domain spanning 
anino acids 319-360 has been solved by multidimensional 
NMR [20]. The domain was found to form a 20 kDa symmetric 
tel :amer made up from a dimer of dimers which comprise two 
an iparallel helices linked by an antiparalM fl sheet. The turn 
sp, nning amino acids 334-337 which links the helices to the 
fl sheets is likely to be exposed to the surface of the p53 protein 
[21 ]. Actually this is in good agreement with the mapped site 
fo tmsl binding on the p53 protein spanning from amino acids 
33 t-339 as it is indicated in Fig. 5. 
dost of the p53 mutations detected in human tumours map 
to the core domain of p53 which seems to be responsible for 
th, specific DNA binding of p53 and apart from stop and 
fn  meshift mutations only four point mutations within the C- 
te1~ninus of p53 have been reported. Three out of these four 
pont  mutations are located within the mentioned turn region, 
na nely Leu33°--~His, Gly334--->Val and Arg'5~Cys [40~2]. It 
w~ s reasoned that these point mutations are potentially desta- 
bil zing the tetrameric structure of p53 since they are located 
at sites nearby the helix and fl sheet interactions [20]. This 
im )lies that either tmsl-p53 complex formation requires the 
olJ ;omerization of p53 or these mutants are still capable for 
olJ;omerisation however fail to bind proteins like the tmsl 
7 8 9 10 11 12 
1 2 3 4 5 6 
Fig. 4. tmsl binding assy on the peptide library. The membrane carry- 
ing the peptide library was probed with purified 32p-labelled tmsl pro- 
tei1~, washed and subjected toautoradiography. 
tmsl tmsl 
355 355 
tins1 tmsl 
Fig. 5. Tetramerization domain of p53. The cartoon represents the p53 
tetramerization domain according to the published three-dimensional 
structure [20] showing the mapped tmsl binding sites. 
protein which are likely to modulate p53 function. These issues 
are currently being addressed. 
Acknowledgements: We would like to thank J. Gfinther for technical 
support and all the members ofProf. Montenarh's lab. This work was 
supported by DFG grants Wa 826/1-4 and Mo 30917-1. 
References 
[1] Greenblatt, M.S., Bennett, W.R, Hollstein, M. and Harris, C.C. 
(1994) Cancer Res. 54, 48554878. 
[2] Harvey, D.M. and Levine, A.J. (1991) Genes Dev. 5, 2375-2385. 
[3] Lane, D.R and Benchimol, S. (1990) Genes Dev. 4, 1-8. 
[4] Selter, H. and Montenarh, M. (1994) Int. J. Biochem. 26, 145-154. 
[5] Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. and Kastan, M.B. 
(1992) Proc. Natl. Acad. Sci. USA 89, 7491-7495. 
[6] Lee, J.M. and Bernstein, A. (1993) Proc. Natl. Acad. Sci. USA 90, 
5742-5746. 
[7] Kastan, M.B. (1993) Adv. Exp. Med. Biol. 339, 291-293. 
[8] Oren, M. (1992) Cancer Metastasis Rev. 11, 141 148. 
[9] Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. and 
Jacks, T. (1993) Nature 362, 847-849. 
[10] Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman, P., 
Prives, C. and Vogelstein, B. (1991) Science 252, 1708-1711. 
[I 1] Zauberman, A., Barak, Y., Ragimov, N., Levy, N. and Oren, M. 
(1993) EMBO J. 12, 279%2808.[12] Hupp, T.R., Meek, D.W., 
Midgley, C.A. and Lane, D.P. (1992) Cell 71,875-886. 
[13] Fields, S. and Jang, S.K. (1990) Science 249, 1046-1049. 
[14] Zhan, Q., Bae, I., Kastan M.B. and Fornace, A.J. (1994) Cancer 
Res. 54, 2755-2760115] Momand, J., Zambetti, G.R, Olson, D.C., 
George, D. and Levine, A.J. (1992) Cell 69, 1237 1245. 
[16] Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, 
S.J. (1994) Cell 75, 805-816. 
[17] EI-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy~ D.B., Parsons, 
R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W. and Vogel- 
stein, B. (1993) Cell 75, 817-825. 
[18] Cho, Y., Gorina, S., Jeffrey, P.D. and Pavletich, N.R (1994) Sci- 
ence 265. 346-355.[19] Stfirzbecher, H.-W., Brain, R.. Addison, C., 
Rudge, K., Remm, M., Grimaldi, M., Keenan, E. and Jenkins, 
J.R. (1992) Oncogene 7, 1513 1523. 
[20] Clore, G.M., Omicbinski, J.G., Sakaguchi, K., Zambrano, N., 
Sakamoto, H., Appella, E. and Gronenborn, A.M. (1994) Science 
265, 386-391. 
[21] Hupp T.R. and Lane, D.P. (1994) Current Biology 4, 865-875. 
[22] Pietenpol, J.A. and Vogelstein, B. (1993) Nature 365, 17-18. 
[23] Issinger, O.-G. (1993) Pharmacol. Ther. 59, 1--30. 
[24] Herrmann, C.RE., Kraiss, S. and Montenarh, M. (1991) Onco- 
gene 6, 877-884. 
158 P. Wagner et al./FEBS Letters 377 (1995) 155-158 
[25] Wagner, P., Appel, K., Issinger, O.G. and Montenarh, M. (1994) 
Int.J.Oncol. 4, 491-498.[26] Wagner, P., Grimaldi, M. and Jenkins, 
J.R. (1993) Eur. J. Biochem. 217, 731-736. 
[27] Wagner, P. (1994) Int. J. Oncol. 4, 987-992. 
[28] Appel, K., Schneider, E., Wagner, P., H6og, J.-O., Karlsson, C. 
and Montenarh, M. (1994) Int. J. Oncol. 5, 667-673. 
[29] Wagner, P. Fuchs, A. and Nastainczyk, W. (1995) Int. J. Oncol. 
7, 171 175. 
[30] Li, B.°L., Langer, J.A., Schwartz, B. and Pestka, S. (1989) Proc. 
Natl. Acad. Sci. USA 86, 558-562. 
[31] Hochuli, E., Bannwarth, W., D6beli, H., Gentz, R. and Stfiber, D. 
(1988) Biotechnology 1321-1325. 
[32] Wagner, P., Hengst, L. and Gallwitz, D. (1992) Methods Enzymol. 
219, 369-387. 
[33] Bischoff, J.R., Friedman, EN., Marshak, D.R., Prives, C. and 
Beach, D. (1990) Proc. Natl. Acad. Sci. USA 87, 4766-4770. 
[34] Stiirzbecher, H.-W., Maimets, T., Chumakov, P., Brain, R., Ad- 
dison, C., Simanis, V., Rudge, K., Philp, R., Grimaldi, M., Court, 
W. and Jenkins, J.R. (1990) Oncogene 5, 795-802. 
[35] Wang, Y. and Prives, E (1995) Nature 376, 88-91. 
[36] Appel, K., Wagner, P., Boldyreff, B., Issinger, O.G. and Monte- 
narh, M. (1995) Oncogene, in press. 
[37] Harlow, E., Crawford, L.V., Pim, D.C. and Williamson, N.M. 
(1981) J. Virol. 39, 861-869. 
[38] Wagner, P., Waschow, C., Nastainczyk, W. and Montenarh, M. 
(1994) Hybridoma 13, 527-529. 
[39] Schneider, E., Fuchs, A., Nastainczyk, W., Montenarh, M. and 
Wagner, P. (1995) Hybridoma 14, 329-333. 
[40] Liu, F., Kohler, M.F., Marks, J.R., Bast, R.C., Boyd, J. and 
Berchuck, A. (1994)Obstet. Gynecol. 83, 118-124. 
[41] D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., 
Russell, E., Johnson, B., Buchhagen, D., Bodner, S. and Phelps, 
R. (1992) Oncogene 7, 339-346. 
[42] Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, 
D.W., Ikenega, M., Imura, H. and Ishizaki, K. (1993) Cancer Res. 
53, 368-372. 
